Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

GLP-1 mimetics as a potential therapy for nonalcoholic steatohepatitis
Yan Chen, Ying-na Xu, Chen-yu Ye, et al.
Acta Pharmacologica Sinica (2021) Vol. 43, Iss. 5, pp. 1156-1166
Open Access | Times Cited: 20

Showing 20 citing articles:

PPAR-γ signaling in nonalcoholic fatty liver disease: Pathogenesis and therapeutic targets
Hao Chen, Huabing Tan, Juan Wan, et al.
Pharmacology & Therapeutics (2023) Vol. 245, pp. 108391-108391
Closed Access | Times Cited: 103
Association of metabolic-dysfunction associated steatotic liver disease with polycystic ovary syndrome
Qiuyu Xu, Jie Zhang, Yan Lü, et al.
iScience (2024) Vol. 27, Iss. 2, pp. 108783-108783
Open Access | Times Cited: 11
GLP-1 receptor agonist as a modulator of innate immunity
Jun Chen, Aihua Mei, Yingying Wei, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 34
The pleiotropic effects of glucagon-like peptide-1 receptor agonists in patients with metabolic dysfunction-associated steatohepatitis: a review for gastroenterologists
Naim Alkhouri, Michael Charlton, Meagan Gray, et al.
Expert Opinion on Investigational Drugs (2025)
Closed Access
Carboxylesterase 2A gene knockout or enzyme inhibition alleviates steatohepatitis in rats by regulating PPARγ and endoplasmic reticulum stress
Jie Liu, Luyao Deng, Bingyi Yao, et al.
Free Radical Biology and Medicine (2025)
Closed Access
Effects of GLP-1 and Other Gut Hormone Receptors on the Gastrointestinal Tract and Implications in Clinical Practice
Michael Camilleri, Camille Lupiañez-Merly
The American Journal of Gastroenterology (2023) Vol. 119, Iss. 6, pp. 1028-1037
Closed Access | Times Cited: 10
Trilobatin alleviates non-alcoholic fatty liver disease in high-fat diet plus streptozotocin-induced diabetic mice by suppressing NLRP3 inflammasome activation
Zhi‐Tong Zhang, Wen-Jiao He, Simin Deng, et al.
European Journal of Pharmacology (2022) Vol. 933, pp. 175291-175291
Closed Access | Times Cited: 17
Novel role for epalrestat: protecting against NLRP3 inflammasome-driven NASH by targeting aldose reductase
Wei Shi, Guang Xu, Yuan Gao, et al.
Journal of Translational Medicine (2023) Vol. 21, Iss. 1
Open Access | Times Cited: 9
Pharmaceutical Strategies to Improve Druggability of Potential Drug Candidates in Nonalcoholic Fatty Liver Disease Therapy
Reeju Amatya, Dong-Hee Lee, Kyoung Ah Min, et al.
Pharmaceutics (2023) Vol. 15, Iss. 7, pp. 1963-1963
Open Access | Times Cited: 7
Liraglutide With Metformin Therapy Ameliorates Hepatic Steatosis and Liver Injury in a Mouse Model of Non-alcoholic Steatohepatitis
Hong‐Yi Chiu, Shih‐Chang Tsai, Fuu‐Jen Tsai, et al.
In Vivo (2023) Vol. 37, Iss. 3, pp. 1037-1046
Open Access | Times Cited: 6
Precision nutrition for targeting pathophysiology of cardiometabolic phenotypes
Chris E. Shannon, Méabh B. Ní Chathail, Sinéad M. Mullin, et al.
Reviews in Endocrine and Metabolic Disorders (2023) Vol. 24, Iss. 5, pp. 921-936
Open Access | Times Cited: 4
All about NASH: disease biology, targets, and opportunities on the road to NASH drugs
H. Eric Xu, Jinsong Guo
Acta Pharmacologica Sinica (2022) Vol. 43, Iss. 5, pp. 1101-1102
Open Access | Times Cited: 3
Nutraceutical and dietary measures with potential for preventing/controlling non-alcoholic fatty liver disease and its complications
Lidianys María Lewis Lujan, Mark F. McCarty, J.C. Galvez-Ruiz, et al.
Human Nutrition & Metabolism (2024) Vol. 37, pp. 200281-200281
Open Access
Tirzepatide protects against hepatic oxidative stress in high-fat induced obesity in male rats
Ashraf Jameel Alathary, Zahraa Jawad Kadhim
Deleted Journal (2024) Vol. 3, Iss. 3
Open Access
Are GLP-1 Analogues a New Solution for the Treatment of NAFLD?
Maria Sudoł, Katarzyna Dąbek, Michał Ochwat, et al.
Quality in Sport (2024) Vol. 35, pp. 56304-56304
Open Access
The Beneficial Effects of GLP-1 Receptor Agonists Other than Their Anti-Diabetic and Anti-Obesity Properties
Chenqi Lu, Cong Xu, Jun Yang
Medicina (2024) Vol. 61, Iss. 1, pp. 17-17
Open Access
Pharmaceutical Strategies to Make Better Drugs for Nonalcoholic Fatty Liver Disease Therapy
Reeju Amatya, Dong-Hee Lee, Kyoung Ah Min, et al.
(2023)
Open Access | Times Cited: 1
Tirzepatide: A First-in-class Twincretin for the Management of Type 2 Diabetes
Shalini Jaswal, Priya Bisht, Rajiv Patel, et al.
Letters in Drug Design & Discovery (2023) Vol. 21, Iss. 6, pp. 991-997
Closed Access
Research Progress on Mechanism of Glucagon-Like Peptide-1 and Aortic Valve Calcification
盼 张
Advances in Clinical Medicine (2023) Vol. 13, Iss. 04, pp. 6439-6449
Closed Access
O uso dos incretinomiméticos no tratamento da obesidade: uma revisão de literatura
Mateus Rodrigues Linhares, Arthur Vinicios Araújo De Souza, Franciely dos Passos Pereira, et al.
STUDIES IN HEALTH SCIENCES (2023) Vol. 5, Iss. 1, pp. 28-39
Open Access
Page 1

Scroll to top